MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Depreciation & Amortization 2011-2026 | ALNY
Annual Depreciation & Amortization Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.7 M | 56.7 M | 54.1 M | 44.5 M | 47.6 M | 34.8 M | 17.2 M | 15.2 M | 13.4 M | 15.1 M | 19 M | 11.9 M | 10.2 M | 9.04 M | 5.12 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.7 M | 5.12 M | 27.3 M |
Quarterly Depreciation & Amortization Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 14.4 M | - | - | - | 13.5 M | - | - | - | 14.1 M | - | 30.2 M | - | 9.46 M | - | 36.2 M | - | 12.6 M | - | 24.4 M | 15.8 M | 7.61 M | - | 11.7 M | 7.69 M | 3.84 M | - | 5.82 M | 5.42 M | 3.18 M | - | 9.65 M | 6.07 M | 3 M | - | 12.1 M | 8.61 M | 4.6 M | - | 14 M | 8.71 M | 3.69 M | - | 8.58 M | 5.47 M | 2.6 M | - | 7.6 M | 4.84 M | 2.13 M | - | 7.01 M | 4.73 M | 2.12 M | - | 3.89 M | 2.63 M | 1.34 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.2 M | 1.34 M | 9.17 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.68 | 4.04 % | $ 197 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | China |
 |
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | USA |
 |
Compugen Ltd.
CGEN
|
475 K | $ 2.7 | -3.75 % | $ 252 M |  Israel |
 |
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
332 K | $ 0.69 | -3.83 % | $ 31.5 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
4.04 M | $ 31.64 | -2.92 % | $ 851 M | USA |
 |
Esperion Therapeutics
ESPR
|
105 K | $ 3.13 | -0.16 % | $ 651 M | USA |
|
Forte Biosciences
FBRX
|
64 K | $ 21.79 | 0.93 % | $ 282 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | USA |
 |
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
1.74 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
58.8 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
5.37 M | $ 14.75 | -0.91 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.45 | 1.47 % | $ 5.68 M | Israel |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
7.72 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 20.94 | 0.38 % | $ 2.66 B | USA |